Cargando…

PD-1 Immune Checkpoint Blockade and PSGL-1 Inhibition Synergize to Reinvigorate Exhausted T Cells

Chronic viral infections where the antigen persists long-term, induces an exhaustion phenotype in responding T cells. It is now evident that immune checkpoints on T cells including PD-1, CTLA-4, and PSGL-1 (Selplg) are linked with the differentiation of exhausted cells. Chronic T cell receptor signa...

Descripción completa

Detalles Bibliográficos
Autores principales:	Viramontes, Karla M., Neubert, Emily N., DeRogatis, Julia M., Tinoco, Roberto
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9237324/ https://www.ncbi.nlm.nih.gov/pubmed/35774790 http://dx.doi.org/10.3389/fimmu.2022.869768

Ejemplares similares

PSGL-1 Immune Checkpoint Inhibition for CD4(+) T Cell Cancer Immunotherapy
por: DeRogatis, Julia M., et al.
Publicado: (2021)

Reinvigorating exhausted HIV-specific T cells via PD-1–PD-1 ligand blockade
por: Freeman, Gordon J., et al.
Publicado: (2006)

HMGB2 regulates the differentiation and stemness of exhausted CD8(+) T cells during chronic viral infection and cancer
por: Neubert, Emily N., et al.
Publicado: (2023)

Strategies to reinvigorate exhausted CD8(+) T cells in tumor microenvironment
por: Guan, Qianting, et al.
Publicado: (2023)

PSGL-1 Is a T Cell Intrinsic Inhibitor That Regulates Effector and Memory Differentiation and Responses During Viral Infection
por: Tinoco, Roberto, et al.
Publicado: (2021)

Epitherapy and immune checkpoint blockade: using epigenetic reinvigoration of exhausted and dysfunctional T cells to reimburse immunotherapy response
por: McGoverne, Isabella, et al.
Publicado: (2020)

T-Cell Exhaustion in Chronic Infections: Reversing the State of Exhaustion and Reinvigorating Optimal Protective Immune Responses
por: Saeidi, Alireza, et al.
Publicado: (2018)

PSGL-1: a novel immune checkpoint driving T-cell dysfunction in obstructive sleep apnea
por: Díaz-García, Elena, et al.
Publicado: (2023)

Targeting Nuclear LSD1 to Reprogram Cancer Cells and Reinvigorate Exhausted T Cells via a Novel LSD1-EOMES Switch
por: Tu, Wen Juan, et al.
Publicado: (2020)

Indirect Impact of PD-1/PD-L1 Blockade on a Murine Model of NK Cell Exhaustion
por: Alvarez, Maite, et al.
Publicado: (2020)

Distinct Dynamics of Migratory Response to PD-1 and CTLA-4 Blockade Reveals New Mechanistic Insights for Potential T-Cell Reinvigoration following Immune Checkpoint Blockade
por: Safaeifard, Fateme, et al.
Publicado: (2022)

Different Expression Characteristics of LAG3 and PD-1 in Sepsis and Their Synergistic Effect on T Cell Exhaustion: A New Strategy for Immune Checkpoint Blockade
por: Niu, Bailin, et al.
Publicado: (2019)

Targeting the NANOG/HDAC1 axis reverses resistance to PD-1 blockade by reinvigorating the antitumor immunity cycle
por: Oh, Se Jin, et al.
Publicado: (2022)

PD-1 Blockade Modulates Functional Activities of Exhausted-Like T Cell in Patients With Cutaneous Leishmaniasis
por: Garcia de Moura, Renan, et al.
Publicado: (2021)

Sunitinib Exerts In Vitro Immunomodulatory Activity on Sarcomas via Dendritic Cells and Synergizes With PD-1 Blockade
por: Ocadlikova, Darina, et al.
Publicado: (2021)

Relevance of PSGL-1 Expression in B Cell Development and Activation
por: González-Tajuelo, Rafael, et al.
Publicado: (2020)

4-1BB co-stimulation further enhances anti-PD-1-mediated reinvigoration of exhausted CD39(+) CD8 T cells from primary and metastatic sites of epithelial ovarian cancers
por: Leem, Galam, et al.
Publicado: (2020)

Hierarchical transcriptional network governing heterogeneous T cell exhaustion and its implications for immune checkpoint blockade
por: Tian, Weihong, et al.
Publicado: (2023)

Reversal of the CD8(+) T-Cell Exhaustion Induced by Chronic HIV-1 Infection Through Combined Blockade of the Adenosine and PD-1 Pathways
por: Li, Jing, et al.
Publicado: (2021)

PSGL-1 Blockade Induces Classical Activation of Human Tumor-associated Macrophages
por: Kauffman, Kevin, et al.
Publicado: (2023)

Functional Exhaustion of HBV-Specific CD8 T Cells Impedes PD-L1 Blockade Efficacy in Chronic HBV Infection
por: Ferrando-Martinez, Sara, et al.
Publicado: (2021)

PD-1 Blockade Promotes Emerging Checkpoint Inhibitors in Enhancing T Cell Responses to Allogeneic Dendritic Cells
por: Stecher, Carmen, et al.
Publicado: (2017)

Natural Killer T-Cell Agonist α-Galactosylceramide and PD-1 Blockade Synergize to Reduce Tumor Development in a Preclinical Model of Colon Cancer
por: Wang, Ying, et al.
Publicado: (2020)

CTLA-4 Synergizes With PD1/PD-L1 in the Inhibitory Tumor Microenvironment of Intrahepatic Cholangiocarcinoma
por: Guo, Xiao-Jun, et al.
Publicado: (2021)

Blockade of the PD-1/PD-L1 Immune Checkpoint Pathway Improves Infection Outcomes and Enhances Fungicidal Host Defense in a Murine Model of Invasive Pulmonary Mucormycosis
por: Wurster, Sebastian, et al.
Publicado: (2022)

EPS reinvigorated
Publicado: (1973)

Ex vivo modelling of PD-1/PD-L1 immune checkpoint blockade under acute, chronic, and exhaustion-like conditions of T-cell stimulation
por: Roberts, Alexander, et al.
Publicado: (2021)

CD38 identifies pre-activated CD8+ T cells which can be reinvigorated by anti-PD-1 blockade in human lung cancer
por: Wu, Pin, et al.
Publicado: (2021)

Progress and Challenges in Precise Treatment of Tumors With PD-1/PD-L1 Blockade
por: Jiang, Youhai, et al.
Publicado: (2020)

Recent developments in PD-1/PD-L1 blockade research for gastroesophageal malignancies
por: Chen, Meng, et al.
Publicado: (2022)

From rough to precise: PD-L1 evaluation for predicting the efficacy of PD-1/PD-L1 blockades
por: Zhao, Xuan, et al.
Publicado: (2022)

Reinvigorating tumour-infiltrating lymphocytes from checkpoint inhibitor resistant melanomas
por: Silva, Inês Pires da, et al.
Publicado: (2018)

Immunogenic Cell Death Inducing Fluorinated Mitochondria‐Disrupting Helical Polypeptide Synergizes with PD‐L1 Immune Checkpoint Blockade
por: Jeong, Seong Dong, et al.
Publicado: (2021)

Current Advances in PD-1/PD-L1 Blockade in Recurrent Epithelial Ovarian Cancer
por: Zhang, Yuedi, et al.
Publicado: (2022)

Combining PD-1/PD-L1 blockade with type I interferon in cancer therapy
por: Razaghi, Ali, et al.
Publicado: (2023)

Fc-null anti-PD-1 monoclonal antibodies deliver optimal checkpoint blockade in diverse immune environments
por: Moreno-Vicente, Julia, et al.
Publicado: (2022)

Impact of CD4 T cells on intratumoral CD8 T-cell exhaustion and responsiveness to PD-1 blockade therapy in mouse brain tumors
por: Khan, Saad M, et al.
Publicado: (2022)

PD-1/PD-L1 checkpoint inhibitors in advanced hepatocellular carcinoma immunotherapy
por: Li, Qian, et al.
Publicado: (2022)

Reinvigorating electrochemistry education
por: Kempler, Paul A., et al.
Publicado: (2021)

PD-1 Blockade Reverses Obesity-Mediated T Cell Priming Impairment
por: Le, Catherine T., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_96ivrjei194tmlsa9rg7ls80rt